REFERENCES
- Gilbert PB, DeGruttola V, Hammer SM, Kuritzkes DR. Viro-logic and regimen termination surrogate end points in AIDS clinical trials. JAMA. 2001;285(6):777–784.
- Journot V, Chene G, Joly P, et al. Viral load as a primary outcome in human immunodeficiency virus trials: a review of statistical analysis methods. Contr Clin Trial. 2001;22(6):639–658.
- Ledergerber B, Egger M, Opravil M, et al. Clinical progres-sion and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lan-cet. 1999;353(9156):863–868.
- Staszewski S, Miller V, Sabin C, et al. Virological response to protease inhibitor therapy in an HIV clinic cohort. AIDS. 1999;13(3):367–373.
- Phillips AN, Staszewski S, Weber R, et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA. 2001;286(20):2560–2567.
- Molina JM, Chene G, Ferchal F, et al. The ALB! trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated pa-tients infected with human immunodeficiency virus. J In-fect Dis. 1999;180(2):351–358.
- Delta Coordinating Committee and Delta Virology Commit-tee. HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial: an extended virology study. AIDS. 1999;13(1):57–65.
- Hughes JP. Mixed effects models with censored data with application to HIV RNA levels. Biometrics. 1999;55(2):625–629.
- Jacqmin-Gadda H, Thiebaut R, Chêne G, Commenges D. Analysis of left-censored longitudinal data with application to viral load in HIV infection. Biostatistics. 2000;1(4):355–368.
- Henderson R, Diggle P, Dobson A. Joint modelling of longi-tudinal measurements and event time data. Biostatistics. 2000;1(4):465–480.